<DOC>
	<DOCNO>NCT01152437</DOCNO>
	<brief_summary>This Phase II study open patient metastatic colorectal cancer try failed chemotherapy regimens contain oxaliplatin irinotecan . Patients must receive anti-EGFR ( Epidermal Growth Factor Receptor ) treatment ( example , cetuximab , panitumumab ) past . Patients wild-type KRAS ( v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ) colorectal cancer randomise receive either BIBW 2992 cetuximab . Patients KRAS mutate colorectal cancer randomise , receive BIBW 2992 . The main objective study : compare effectiveness BIBW 2992 cetuximab patient KRAS wild type cancer , assess effectiveness BIBW 2992 patient KRAS mutate cancer .</brief_summary>
	<brief_title>A Study BIBW 2992 ( Afatinib ) Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients metastatic colorectal cancer fail oxaliplatin irinotecanbased regimen 2 . Tumour sample available KRAS ( vKiras2 Kirsten rat sarcoma viral oncogene homolog ) mutation test biomarker analysis . Exclusion criterion : 1 . Prior treatment Epidermal Growth Factor Receptor ( EGFR ) target small molecule antibody . 2 . Biological treatment ( include Bevacizumab antiangiogenic agent ) trial allow . 3 . Known preexist interstitial lung disease . 4 . Planned major surgical procedure trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>